Albumin Binding and Half-Life Extension

Why albumin?

Human serum albumin is the most abundant plasma protein and carries endogenous long-chain fatty acids between tissues. It has multiple well-characterised hydrophobic binding sites that bind saturated and unsaturated fatty acids with dissociation constants in the low-micromolar range. A peptide functionalised with a fatty-acid moiety can occupy these sites and inherit the slow turnover of the endogenous fatty-acid pool.^[2]

Reversible, non-covalent, saturable

Albumin binding here is reversible and non-covalent. The equilibrium continuously releases small amounts of free peptide, which is the fraction available to engage the receptor and to be cleared. Because most of the peptide is albumin-bound at any moment, renal filtration and proteolytic clearance are dramatically reduced compared with the native peptide.

Chemistry — mono-acid vs di-acid

• Liraglutide uses a C16 mono-acid attached at Lys26 via a γGlu linker. The resulting albumin affinity supports a plasma half-life of approximately 13 hours in humans — long enough for once-daily dosing.
• Semaglutide uses a C18 fatty-di-acid attached at Lys26 through a longer γGlu-2xOEG linker. The di-acid geometry and longer spacer support tighter, more sustained albumin binding, yielding a plasma half-life of approximately one week and once-weekly dosing.^[1][2]

Why DPP-4 resistance also matters

Albumin binding alone would not be sufficient if the small free fraction were still rapidly degraded by DPP-4. Long-acting GLP-1 analogues therefore combine albumin binding with a DPP-4-resistant substitution (Aib8 or an equivalent modification), so that both distribution and enzymatic clearance are addressed simultaneously.^[1]

Assay implications

In cell-based assays, apparent potency of albumin-binding peptides depends strongly on the albumin concentration in the buffer. Reported EC₅₀ values in high-albumin media can be an order of magnitude higher than in albumin-free media because a large fraction of nominal ligand is sequestered. Comparability between laboratories requires reporting buffer composition, plasticware and incubation geometry.

Related reading: Semaglutide monograph, What is Semaglutide, Semaglutide mechanism of action, GLP-1 receptor explained, Retatrutide monograph, Triple agonists explained, Research Use Only and Testing & Quality Control.